Ception's Cinquil meets one of two endpoints

Ception Therapeutics Inc. (Malvern, Pa.) said Cinquil reslizumab met the co-primary endpoint of significantly reducing esophageal eosinophil levels vs. placebo in the Phase IIb/III Res-05-0002 trial to treat eosinophilic esophagitis in pediatric patients (p<0.0001). However, the mAb against IL-5 missed the co-primary endpoint of significantly improving clinical symptoms as measured by Physician's Global Assessment vs. placebo. The company said patients treated with placebo had an "unexpectedly large improvement in their symptoms," but said it is too early to speculate why. The four-month, double-blind trial enrolled 226 patients aged 5-18 ...